---
title: Venetoclax-based salvage therapy as bridge-to-transplant is feasible and effective
  in patients with relapsed/refractory AML
date: '2024-09-18'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39293081/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240918184842&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: The BCL2-inhibitor Venetoclax (VEN) in combination with hypomethylating
  agents (HMA) has been approved for first-line treatment of acute myeloid leukemai
  (AML) patients ineligible for intensive treatment. Emerging Data suggest that VEN
  containing treatment strategies may also be effective in relapsed/refractory (R/R)
  AML, however, comparative studies with conventional treatment strategies for medically
  fit patients as a bridge-to transplant strategy are limited. Using propensity score
  ...
disable_comments: true
---
The BCL2-inhibitor Venetoclax (VEN) in combination with hypomethylating agents (HMA) has been approved for first-line treatment of acute myeloid leukemai (AML) patients ineligible for intensive treatment. Emerging Data suggest that VEN containing treatment strategies may also be effective in relapsed/refractory (R/R) AML, however, comparative studies with conventional treatment strategies for medically fit patients as a bridge-to transplant strategy are limited. Using propensity score ...